Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model

Simple item page
dc.contributor.authorCortinez, L. I.
dc.contributor.authorAnderson, B. J.
dc.contributor.authorPenna, A.
dc.contributor.authorOlivares, L.
dc.contributor.authorMunoz, H. R.
dc.contributor.authorHolford, N. H. G.
dc.contributor.authorStruys, M. M. R. F.
dc.contributor.authorSepulveda, P.
dc.date.accessioned2024-01-10T13:49:27Z
dc.date.available2024-01-10T13:49:27Z
dc.date.issued2010
dc.description.abstractThe objective of this study was to develop a pharmacokinetic (PK) model to characterize the influence of obesity on propofol PK parameters.
dc.description.abstractNineteen obese ASA II patients undergoing bariatric surgery were studied. Patients received propofol 2 mg kg(-1) bolus dose followed by a 5-20-40-120 min, 10-8-6-5 mg kg(-1) h(-1) infusion. Arterial blood samples were withdrawn at 1, 3, 5 min after induction, every 10-20 min during propofol infusion, and every 10-30 min for 2 h after stopping the propofol infusion. Arterial samples were processed by high-performance liquid chromatography. Time-concentration data profiles from this study were pooled with data from two other propofol PK studies available at http://www.opentci.org Population PK modelling was performed using non-linear mixed effects model.
dc.description.abstractThe study involved 19 obese adults who contributed 163 observations. The pooled analysis involved 51 patients (weight 93 sd 24 kg, range 44-160 kg; age 46 sd 16 yr, range 25-81 yr; BMI 33 sd 9 kg m(-2), range 16-52 kg m(-2)). A three-compartment model was used to investigate propofol PK. An allometric size model using total body weight (TBW) was superior to all other models investigated (linear TBW, free fat mass, lean body weight, normal fat mass) for all clearance parameters. Variability in V2 and Q2 was reduced by a function showing a decrease in both parameters with age.
dc.description.abstractWe have derived a population PK model using obese and non-obese data to characterize propofol PK over a wide range of body weights. An allometric model using TBW as the size descriptor of volumes and clearances was superior to other size descriptors to characterize propofol PK in obese patients.
dc.fechaingreso.objetodigital2024-04-30
dc.format.extent9 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1093/bja/aeq195
dc.identifier.eissn1471-6771
dc.identifier.issn0007-0912
dc.identifier.pubmedidMEDLINE:20710020
dc.identifier.urihttps://doi.org/10.1093/bja/aeq195
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/79452
dc.identifier.wosidWOS:000281950500009
dc.information.autorucMedicina; Cortinez LI;S/I;79356
dc.information.autorucMedicina;Munoz HR;S/I;73573
dc.issue.numero4
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final456
dc.pagina.inicio448
dc.publisherELSEVIER SCI LTD
dc.revistaBRITISH JOURNAL OF ANAESTHESIA
dc.rightsacceso restringido
dc.subjectanaesthetics i
dc.subjectv
dc.subjectpropofol
dc.subjectobesity
dc.subjectpharmacokinetics
dc.subjectTARGET-CONTROLLED INFUSION
dc.subjectPREDICTIVE PERFORMANCE
dc.subjectSIZE DESCRIPTOR
dc.subjectANESTHESIA
dc.subjectWEIGHT
dc.subjectAGE
dc.subjectPHARMACODYNAMICS
dc.subjectQUANTIFICATION
dc.subjectREMIFENTANIL
dc.subjectCLEARANCE
dc.titleInfluence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model
dc.typeartículo
dc.volumen105
sipa.codpersvinculados79356
sipa.codpersvinculados73573
sipa.indexWOS
sipa.indexScopus
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Influence of obesity on propofol pharmacokinetics derivation of a pharmacokinetic model.pdf
Size:
3.36 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas